WO2011065769A3 - Cell or culture extract of cladonia macilenta purple and/or biruloquinone as acetylcholinesterase inhibitors - Google Patents

Cell or culture extract of cladonia macilenta purple and/or biruloquinone as acetylcholinesterase inhibitors Download PDF

Info

Publication number
WO2011065769A3
WO2011065769A3 PCT/KR2010/008416 KR2010008416W WO2011065769A3 WO 2011065769 A3 WO2011065769 A3 WO 2011065769A3 KR 2010008416 W KR2010008416 W KR 2010008416W WO 2011065769 A3 WO2011065769 A3 WO 2011065769A3
Authority
WO
WIPO (PCT)
Prior art keywords
biruloquinone
purple
cell
culture extract
acetylcholinesterase inhibitors
Prior art date
Application number
PCT/KR2010/008416
Other languages
French (fr)
Other versions
WO2011065769A2 (en
Inventor
Jae-Seoun Hur
Young Jin Koh
Chang Tian Li
Heog Nuo
Original Assignee
Industry-Academy Cooperation Corps. Of Sunchon National University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry-Academy Cooperation Corps. Of Sunchon National University filed Critical Industry-Academy Cooperation Corps. Of Sunchon National University
Priority to CN201080053638.1A priority Critical patent/CN102666836B/en
Publication of WO2011065769A2 publication Critical patent/WO2011065769A2/en
Publication of WO2011065769A3 publication Critical patent/WO2011065769A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
    • C07C2603/50—Pyrenes; Hydrogenated pyrenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention relates to cell or culture extract of Cladonia macilenta purple, biruloquinone and pharmaceutically acceptable salts thereof which have acetylcholinesterase (AChE) inhibitory activity, and pharmaceutical composition and functional food for preventing, treating, or alleviating neurodegenerative disease, myasthenia of smooth muscle of gastrointestinal tract or urinary bladder, or glaucoma, comprising the same.
PCT/KR2010/008416 2009-11-25 2010-11-25 Cell or culture extract of cladonia macilenta purple and/or biruloquinone as acetylcholinesterase inhibitors WO2011065769A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201080053638.1A CN102666836B (en) 2009-11-25 2010-11-25 Cell or culture extract of cladonia macilenta purple and/or biruloquinone as acetylcholinesterase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0114401 2009-11-25
KR1020090114401A KR101140583B1 (en) 2009-11-25 2009-11-25 Acetylcholinesterase inhibitors comprising the extracts of Cladonia macilenta purple or culture borth and/or biruloquinone

Publications (2)

Publication Number Publication Date
WO2011065769A2 WO2011065769A2 (en) 2011-06-03
WO2011065769A3 true WO2011065769A3 (en) 2011-11-10

Family

ID=44067113

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/008416 WO2011065769A2 (en) 2009-11-25 2010-11-25 Cell or culture extract of cladonia macilenta purple and/or biruloquinone as acetylcholinesterase inhibitors

Country Status (3)

Country Link
KR (1) KR101140583B1 (en)
CN (1) CN102666836B (en)
WO (1) WO2011065769A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2467063C1 (en) * 2011-05-05 2012-11-20 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Северо-Восточный федеральный университет имени М.К. Аммосова" Method of producing highly active solid-phase antibiotic biopreparation of reindeer moss from lichen fronds
CN113373098B (en) * 2021-07-28 2022-07-01 西安医学院 Stenotrophomonas H2 strain for treating Alzheimer disease and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100509440B1 (en) 2003-01-14 2005-08-22 임강현 Pharamceutical preparation comprising extract of Yak-kong (Rhynchosia nolubilis) for Alzheimer's disease, dementia, amyosthenia of smooth muscle, and glaucoma
KR100550358B1 (en) 2005-05-20 2006-02-08 임강현 Food product and feed product comprising extract of Yak-kong (Rhynchosia nolubilis or Rhynchosia volubilis) for Alzheimer's disease, dementia, amyosthenia of smooth muscle, and glaucoma
CN101525631A (en) * 2008-03-03 2009-09-09 迈德金生物技术（北京）有限公司 Thallus extract and preparation method thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HERZ, W. ET AL.: "Progress in the chemistry of organic natural products.", PROGRESS IN THE CHEMISTRY OF ORGANIC NATURAL PRODUCTS., vol. 81, 2001, WIEN NEW YORK, pages 195 *
JEE, J-H. ET AL.: "Effects of phenanthrene exposure on the acetyl- cholinesterase activity of olive flounder(Paralichthys olivaceus).", J. FISH. SCI. TECH., vol. 6, no. 4, 2003, pages 225 - 227 *
LUO, 0. ET AL.: "Acetylcholinesterase inhibitor from secondary metabolites of lichen forming fungi Cladonia macilenta.", THE 8TH ANNUAL MEETING OF THE JAPANESE SOCIETY FOR LICHENOLOGY, 12 July 2009 (2009-07-12) *
PODTEROB, A. P.: "Chemical composition of lichens and their medical applications.", PHARMACEUTIAL CHEMISTRY JOURNAL, vol. 42, no. 10, 2008, pages 582 - 588 *

Also Published As

Publication number Publication date
CN102666836B (en) 2015-01-07
WO2011065769A2 (en) 2011-06-03
KR20110057831A (en) 2011-06-01
KR101140583B1 (en) 2012-05-02
CN102666836A (en) 2012-09-12

Similar Documents

Publication Publication Date Title
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
WO2009091898A3 (en) 6-and 7-amino isoquinoline compounds and methods for making and using the same
WO2009064460A3 (en) Gastrointestinal delivery systems
WO2012064973A3 (en) Heterocyclic compounds and uses thereof
WO2010092090A3 (en) Novel salts of sitagliptin
WO2010108074A3 (en) Inhibitors of pi3 kinase
WO2011044506A3 (en) Sulphone compounds for use in the treatment of obesity
EP2192911B8 (en) Plant extract from low-thc cannabis for the treatment of disease
WO2008145688A3 (en) Pyrrolopyridine compounds, process for their preparation, and their use as medicaments
WO2008104978A3 (en) Novel sirna structures
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
WO2010011772A3 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
WO2012149157A3 (en) Heterocyclic compounds for the inhibition of pask
WO2012104263A3 (en) 1,4 oxazines as bace1 and/or bace2 inhibitors
WO2009145456A3 (en) Heterocyclic derivatives
WO2012009715A3 (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
WO2012046030A3 (en) Phosphodiesterase inhibitors
WO2012125981A3 (en) Raf kinase inhibitors
WO2009030952A3 (en) Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
WO2009041663A1 (en) Agent for prevention and/or treatment of skin diseases
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
WO2012119046A3 (en) Heterocyclic compounds for the inhibition of pask
WO2012080195A3 (en) Polymorphic forms of asenapine maleate and processes for their preparation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080053638.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10833581

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10833581

Country of ref document: EP

Kind code of ref document: A2